Thermo Fisher Scientific (TMO) Stock Overview
Provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
TMO Community Fair Values
Create NarrativeSee what 171 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$540.27
FV
16.4% undervalued intrinsic discount7.00%
Revenue growth p.a.
3.1k
users have viewed this narrative1users have liked this narrative
0users have commented on this narrative
24users have followed this narrative
Thermo Fisher Scientific Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$451.79 |
| 52 Week High | US$643.99 |
| 52 Week Low | US$385.46 |
| Beta | 0.88 |
| 1 Month Change | -14.11% |
| 3 Month Change | -12.29% |
| 1 Year Change | 13.44% |
| 3 Year Change | -11.54% |
| 5 Year Change | -1.72% |
| Change since IPO | 14,294.88% |
Recent News & Updates
Narrative Update • May 02
TMO: Revised Profitability And Tools Headwinds Will Shape Returns Through 2026
The analyst price target for Thermo Fisher Scientific has been revised from $575 to $520. Analysts cite updated views on discount rates, revenue growth, profit margins and sector-specific tools headwinds, as reflected in recent target cuts from multiple firms, along with at least one new bullish initiation.Seeking Alpha • Apr 20
Thermo Fisher: Great Business Still Trading At A Risky Price Before Earnings
Summary Thermo Fisher Scientific remains a high-quality, stable business, but its stock is currently overvalued relative to its growth outlook. TMO reported FY25 revenue growth of 3.9% and EPS growth of 7.3%, with management guiding for 6–8% adjusted EPS growth in FY26. Despite solid fundamentals and resilient end markets, valuation multiples near 30x earnings/free cash flow appear stretched unless double-digit growth resumes. I maintain a Hold rating, citing fair-to-rich valuation, cautious analyst revisions, and the need for continued strong execution to justify current prices. Read the full article on Seeking AlphaRecent updates
Narrative Update • May 02
TMO: Revised Profitability And Tools Headwinds Will Shape Returns Through 2026
The analyst price target for Thermo Fisher Scientific has been revised from $575 to $520. Analysts cite updated views on discount rates, revenue growth, profit margins and sector-specific tools headwinds, as reflected in recent target cuts from multiple firms, along with at least one new bullish initiation.Seeking Alpha • Apr 20
Thermo Fisher: Great Business Still Trading At A Risky Price Before Earnings
Summary Thermo Fisher Scientific remains a high-quality, stable business, but its stock is currently overvalued relative to its growth outlook. TMO reported FY25 revenue growth of 3.9% and EPS growth of 7.3%, with management guiding for 6–8% adjusted EPS growth in FY26. Despite solid fundamentals and resilient end markets, valuation multiples near 30x earnings/free cash flow appear stretched unless double-digit growth resumes. I maintain a Hold rating, citing fair-to-rich valuation, cautious analyst revisions, and the need for continued strong execution to justify current prices. Read the full article on Seeking Alpha
Narrative Update • Apr 18
TMO: 2026 Tools Demand And New Platforms Will Drive Performance
Analysts have nudged their price target for Thermo Fisher Scientific lower from about $664 to $648, reflecting updated views that combine slightly higher assumed revenue growth and profit margins with a more conservative future P/E multiple after a mix of recent target raises and trims across the Street. Analyst Commentary Recent research notes on Thermo Fisher Scientific point to a mixed but constructive debate around how much investors should pay for the company, and how execution risks stack up against its growth opportunities.
Narrative Update • Apr 02
TMO: 2026 Tools Recovery And AI Labs Adoption Will Drive Upside
The analyst price target for Thermo Fisher has been adjusted slightly, with the updated fair value moving from about $742.76 to $738.42 as analysts factor in modest tweaks to revenue growth, profit margin, and future P/E assumptions following a series of supportive target increases across recent Street research. Analyst Commentary Recent research points to generally constructive sentiment around Thermo Fisher Scientific, with several bullish analysts revisiting their models, adjusting fair value estimates, and flagging potential catalysts that could influence how investors think about the shares over the next few years.Narrative Update • Mar 19
TMO: 2026 Tools Demand And Recovering End Markets Will Drive Performance
Narrative Update The updated analyst price target for Thermo Fisher Scientific reflects a higher fair value estimate of about $664, with analysts citing modestly stronger revenue growth assumptions, a slightly higher discount rate, and a similar forward P/E outlook despite a lower projected profit margin. Analyst Commentary Recent Street commentary around Thermo Fisher Scientific has been generally constructive, with several firms lifting price targets and pointing to a more supportive backdrop for life science tools into 2026.Narrative Update • Mar 05
TMO: 2026 Tools Recovery And AI Use In Labs Will Support Upside
Analysts have raised their consolidated price target for Thermo Fisher Scientific by about $25, citing updated expectations for steady mid single digit organic growth into 2026, modestly higher profit margins and a slightly lower future P/E multiple. Analyst Commentary Recent street research points to a cluster of higher price targets for Thermo Fisher Scientific, with several bullish analysts updating their models to reflect expectations for mid single digit organic growth into 2026, slightly stronger margins and an adjusted P/E framework.Narrative Update • Feb 19
TMO: 2026 Tools Recovery And AI Partnerships Will Drive Earnings Power
Thermo Fisher Scientific's analyst price targets have moved higher by up to $117 per share, as analysts broadly lift their outlook on the company, citing refined growth and margin assumptions along with a series of recent target increases across the Street. Analyst Commentary Bullish analysts are largely aligned in lifting price targets for Thermo Fisher Scientific, pointing to what they see as an improving setup into 2026 and a company that is executing against refined growth and margin assumptions.Narrative Update • Feb 05
TMO: 2026 Tools Upside And AI Partnerships Will Reshape Earnings Power
Analysts have lifted their fair value estimate for Thermo Fisher Scientific from about $662 to roughly $743, citing updated views on discount rates, revenue growth, profit margins, and future P/E assumptions in light of recent price target increases across the Street. Analyst Commentary Street research around Thermo Fisher Scientific has turned more constructive, with a series of higher price targets that align with the updated fair value estimate.Narrative Update • Jan 22
TMO: Raised 2026 Expectations And Policy Risks Will Pressure Future Returns
Narrative Update Overview The analyst price target for Thermo Fisher Scientific has shifted higher, from about US$541 to US$575, as analysts reflect updated assumptions for slightly faster revenue growth, stronger profit margins, and a lower future P/E multiple, supported by a series of price target increases across recent Street research. Analyst Commentary Recent Street research on Thermo Fisher Scientific has centered on refreshed models out to 2026, with several firms lifting price targets into a US$650 to US$700 range and maintaining positive ratings.Narrative Update • Jan 07
TMO: Life Science Scale And 2026 Tools Demand Will Support Steady Performance
Analysts have nudged their fair value estimate for Thermo Fisher Scientific higher from about $626 to roughly $642, citing a series of recent price target increases that reflect updated models after Q3 results, expectations for healthier end markets and tools demand into 2026, and the company's scale in life science tools and lab supplies. Analyst Commentary Recent Street research on Thermo Fisher Scientific clusters around a consistent, more constructive view on the company, with several firms lifting their fair value estimates following the latest Q3 update.Analysis Article • Jan 05
Unpleasant Surprises Could Be In Store For Thermo Fisher Scientific Inc.'s (NYSE:TMO) Shares
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 19x, you may...Narrative Update • Dec 23
TMO: Life Science Leadership And New Diagnostics Will Drive Balanced Outlook
Thermo Fisher Scientific's fair value estimate has been raised from $450.00 to approximately $541.00. This change reflects analysts' higher price targets following a strong and resilient Q3 performance, solid segment-level results, and expectations that the company will continue to capitalize on its leading position in life science tools and services.Narrative Update • Dec 09
TMO: Life Science Leadership And New Diagnostics Will Support Steady Future Performance
Thermo Fisher Scientific's fair value estimate has been raised modestly to approximately $626 per share, up from about $614, as analysts factor in a series of higher Street price targets in the mid to upper $500s and $600s ranges driven by resilient Q3 execution, stable end markets, and sustained leadership in life science tools and services. Analyst Commentary Recent Street research continues to skew positive, with multiple upward revisions to price targets into the mid to high $500s and low $600s, reinforcing the view that Thermo Fisher's execution and market positioning justify a premium valuation versus peers.Narrative Update • Nov 25
TMO: Recent Product Approvals And Expanding End Markets Will Support Steady Performance
Thermo Fisher Scientific's average analyst price target has increased by a notable margin, as analysts cite robust third-quarter performance and continued strength in key end markets as reasons for their more optimistic outlook. Analyst Commentary Recent analyst activity has led to a series of price target revisions for Thermo Fisher Scientific, reflecting both confidence in the company’s fundamentals and acknowledgement of ongoing sector headwinds.Narrative Update • Nov 07
TMO: Share Gains And Buyback Program Will Offset Sector Risks Ahead
Thermo Fisher Scientific's fair value estimate has increased by approximately $10 to $613.58, as analysts cite recent upward revisions in price targets following stronger-than-expected performance and ongoing sector resilience. Analyst Commentary Recent analyst updates on Thermo Fisher Scientific highlight diverging perspectives on the company's valuation, growth prospects, and sector positioning.Narrative Update • Oct 24
Life Science Leadership And Pharma Partnerships Will Drive Long-Term Market Momentum
Thermo Fisher Scientific's analyst price target has been increased from $554 to $604. This reflects analysts' optimism following stronger-than-expected quarterly results and continued outperformance in key life science segments.Narrative Update • Oct 09
Pharmaceutical And Biotech Expansion Will Fuel Future Success
Thermo Fisher Scientific’s analyst price target has increased by approximately $8 to $554. Analysts cite continued market leadership and resilient long-term fundamentals as supporting factors for further upside for the company.Narrative Update • Sep 25
Pharmaceutical And Biotech Expansion Will Fuel Future Success
Analysts have modestly reduced Thermo Fisher Scientific’s price target to $546.76, balancing optimism over long-term growth catalysts and recent strong performance against short-term headwinds in life sciences R&D and slower anticipated near-term recovery. Analyst Commentary Bullish analysts highlight Thermo Fisher's "one-stop-shop" pharma partnership model, viewing it as a driver for long-term multiple expansion and resilience as a preferred partner in biopharma.Narrative Update • Aug 27
Pharmaceutical And Biotech Expansion Will Fuel Future Success
Analysts raised their price target for Thermo Fisher Scientific to $555.84, citing improved sentiment from strong Q2 results, upward FY25 guidance revisions, and optimism around its resilient pharmaceutical partnership model and recovering end-markets, despite ongoing R&D headwinds. Analyst Commentary Bullish analysts highlight Thermo Fisher's resilient "one-stop-shop" pharma partnership model, expecting it to drive multiple expansion and position the company as a long-term biopharma partner of choice.Analysis Article • Jul 01
Risks To Shareholder Returns Are Elevated At These Prices For Thermo Fisher Scientific Inc. (NYSE:TMO)
Thermo Fisher Scientific Inc.'s ( NYSE:TMO ) price-to-earnings (or "P/E") ratio of 23.5x might make it look like a sell...Shareholder Returns
| TMO | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 1.3% | 1.6% | -0.3% |
| 1Y | 13.4% | 7.1% | 26.7% |
Return vs Industry: TMO exceeded the US Life Sciences industry which returned 7.1% over the past year.
Return vs Market: TMO underperformed the US Market which returned 26.7% over the past year.
Price Volatility
| TMO volatility | |
|---|---|
| TMO Average Weekly Movement | 4.6% |
| Life Sciences Industry Average Movement | 8.2% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: TMO has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: TMO's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1956 | 125,000 | Marc Casper | www.thermofisher.com |
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases.
Thermo Fisher Scientific Inc. Fundamentals Summary
| TMO fundamental statistics | |
|---|---|
| Market cap | US$166.42b |
| Earnings (TTM) | US$6.85b |
| Revenue (TTM) | US$45.20b |
24.5x
P/E Ratio3.7x
P/S RatioIs TMO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TMO income statement (TTM) | |
|---|---|
| Revenue | US$45.20b |
| Cost of Revenue | US$26.70b |
| Gross Profit | US$18.50b |
| Other Expenses | US$11.65b |
| Earnings | US$6.85b |
Last Reported Earnings
Mar 28, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 18.43 |
| Gross Margin | 40.93% |
| Net Profit Margin | 15.15% |
| Debt/Equity Ratio | 82.5% |
How did TMO perform over the long term?
See historical performance and comparisonDividends
0.4%
Current Dividend Yield10%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/20 17:00 |
| End of Day Share Price | 2026/05/20 00:00 |
| Earnings | 2026/03/28 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Thermo Fisher Scientific Inc. is covered by 53 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kadambari Daptardar | Accountability Research Corporation |
| David Toung | Argus Research Company |
| Catherine Ramsey Schulte | Baird |